Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Depreciation & Amortization (CF) (2024 - 2025)

Historic Depreciation & Amortization (CF) for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to $165789.0.

  • Neuphoria Therapeutics' Depreciation & Amortization (CF) fell 19.99% to $165789.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $662637.0, marking a year-over-year increase of 9968.93%. This contributed to the annual value of $662890.0 for FY2025, which is 1.52% down from last year.
  • As of Q4 2025, Neuphoria Therapeutics' Depreciation & Amortization (CF) stood at $165789.0, which was down 19.99% from $165792.0 recorded in Q3 2025.
  • Neuphoria Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $166121.0 during Q4 2024, with a 5-year trough of $165431.0 in Q1 2025.